MAR 31, 2017 2:29 PM PDT

New Multiple Sclerosis Drug Wins FDA Approval

WRITTEN BY: Xuan Pham

The FDA recently approved the first drug for the treatment of relapsing forms of multiple sclerosis (MS). The announcement marks a significant achievement, which is expected to help the 400,000 MS patients in the US.

Multiple sclerosis is described as a demyelinating disease whereby the body’s immune system mistakenly attacks the myelin sheath covers in the brain and spinal cord. This disrupts the electrical signal traveling from the brain to the body, and leads to physical and neurologic disabilities. The progressive form of MS causes patients to slowly deteriorate over time, while the relapsing form causes patients to go through bouts of symptoms and recovery. There is no cure for either form of MS.

“Multiple sclerosis can have a profound impact on a person’s life,” said Billy Dunn, the director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This therapy not only provides another treatment option for those with relapsing MS, but for the first time provides an approved therapy for those with primary progressive MS.”

The drug is known on the market as Ocrevus (ocrelizumab), and it works by weakening the immune system. In particular, IV infusions of Ocrevus prevent the B cells from attacking the protective myelin covers.

Tested in patients with both forms of MS (the progressive form and the relapsing remitting form), Ocrevus seems to stop the inflammation process in the brain. This results in less fatigue and muscle weakness. Vision seems to also be improved. Furthermore, scans show significantly less brain loss with the help of ocrelizumab.

"The drug is so much more effective at shutting down inflammation," said David Hafler, an MS expert from the Yale School of Medicine.

Side effects associated with Ocrevus include infusion-related reactions, such as skin irritation, flushing, shortness of breath, and nausea. In addition, upper respiratory tract infections were among the most common side effect seen with the drug in both forms of MS.

Patients eager to be treated with Ocrevus will have to wait just a few more weeks. Furthermore, they should also be aware that this drug comes with a hefty price tag of $65,000 per year. Though the cost is substantial, it is reportedly on par with approved drugs for the other forms of MS.

Additional sources: CNN

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 14, 2019
Genetics & Genomics
OCT 14, 2019
Researchers Develop a Score to Quantify the Risk of Epilepsy
It usually takes two seizures before a person can be diagnosed with epilepsy. New work can help change that....
NOV 02, 2019
Clinical & Molecular DX
NOV 02, 2019
Forecasting Chronic Pain
Chronic pain comes in many forms. Over half of those suffering from chronic pain, say they experience life-altering levels of pain on a daily basis. Many s...
NOV 14, 2019
Chemistry & Physics
NOV 14, 2019
Examining the Squirrelly Ones: Wearable MEG Scanner that Suits Pediatric Patients
In a recent study, a joint research team at the University of Nottingham, University of Oxford, and University College London successfully tested a ne...
JAN 14, 2020
Clinical & Molecular DX
JAN 14, 2020
Can I eat this donut? A quick test for celiac disease.
Genetic testing revealed that our ancestors have been eating wheat, rye, spelt and barley for over 8,000 years. Today, gluten, a protein found within these...
JAN 06, 2020
Genetics & Genomics
JAN 06, 2020
Some Genetic Sequencing Tests Are Coming Up Short
If it's suspected that a person has a genetic disease, doctors might send the patient's DNA for sequencing. But some sequencing tests may not be checking thoroughly....
FEB 06, 2020
Clinical & Molecular DX
FEB 06, 2020
Concussion detector could pick up concussions in athletes, right from the sidelines
Concussions are brain traumas caused by a blow to the head or a whiplash injury. The risk of concussions are greatly heightened in athletes playing high co...
Loading Comments...